INVEST IN ONEFUL HEALTH, INC. TODAY!
Making Medicines Work Better For You
$81,410.97 Raised
REASONS TO INVEST
Our innovative cardiovascular "polypill" combines 3-7 FDA-approved pharmaceuticals into a single capsule or gel packet tailored to your medical needs. In studies, our formulations have been shown to reduce the risk of heart attacks and strokes by 50% per year
Our robotic automation and online tools enable us to produce personalized treatments in partnership with telemedicine physicians at a price point as low as $1 per day, making personalized medications affordable and accessible to almost everyone.
Invest in OneFul to tap into the personalized medicine industry, which experts indicate that the industry will soon be a trillion-dollar sector. Unlike traditional “One-size-for-all” medicine, our precision technology combined with the latest pharmacogenomics science has the potential to transform healthcare by providing individualized therapies on a mass scale. Our team is equipped with patented robotics, multi-state accredited pharmacy licenses, and an entire operational pharmacy staff. The OneFul pipeline includes customized treatments for major chronic diseases such as diabetes, mental health, and Alzheimer's in the future. Don't miss out on the opportunity to revolutionize healthcare.
the pitch
OneFul Health's mission is to improve the quality of life for millions of patients, through personalized medicine produced with patented pharmacy technology. Our e-pharmacy platform combines precision medicine science and robotic automation to create multi-drug prescriptions as a capsule or easy-to-swallow gel packet. The company is currently focused on launching its personalized “polypill” product for cardiovascular patients and plans to scale to additional markets and health conditions, including mental health and diseases of aging, in the next few years.
A Prescription for Efficient, Individualized Pharmaceutical Therapy
OneFul’s pharmaceutical technology platform is being designed to offer affordable and accessible prescription combination medications, customizable to a variety of health conditions and chronic diseases at the individual level.
*A patented gel packet system has been used in high volume production of personalized nutraceuticals and is planned to be qualified for pharmaceuticals pending bioequivalence testing.
Utilizing patented processes and innovative drug delivery technology, our digital platform is designed to consolidate many approved medications into a single capsule format, with a goal of improving patient adherence, and reducing any adverse effects from treatment. Our regulatory licenses allow us to go to market now without the uncertainty of government approvals using approved pharmaceuticals in high-purity forms. We work with partners who supply genomic analysis and digital health data, and algorithms to formulate each prescription to be the most effective combination of treatments possible for each person.
The Problem & Our Solution
A Scalable Platform Built To Support Tens of Millions with Effective Chronic Disease Treatments
For consumers managing chronic diseases and conditions, current drug therapies typically consist of multiple medications, requiring patients to take as many as 3-7 pills per day. According to recent data, 24% of adults in the U.S. take more than 3 pills per day and the rate of adherence to prescribed treatments is less than 50% (source, source), resulting in at least 100,000 preventable deaths, and $100B in preventable medical costs per year. (source)
In order to consolidate existing prescriptions as well as improve treatment outcomes, OneFul has developed the technology to combine multiple approved drugs and produce a single small capsule or flavored gel packets, containing high-purity doses of the same active drug ingredients.
*A patented gel packet system has been used in high volume production of personalized nutraceuticals and is planned to be qualified for pharmaceuticals pending bioequivalence testing.
Our patented automation platform is capable of producing formulas on-demand, more accurately, and up to 100 times faster than traditional manual compounding, resulting in low-cost, highly-customized, multi-drug treatments. Many of our products cost as little as $1 per day and can be additionally personalized with microdosing to best suit the drug metabolism of each individual patient.
The Market & Our Traction
The Demand and Capacity to Change Personalized Medicine
OneFul’s e-pharmacy has built a customer base of over loyal 3,500 patients, generating annual revenues of over $5M. 15-20% of existing customers surveyed indicate an interest in the cardiovascular polypill concept, translating to a potential waitlist of hundreds. We are in the process of negotiating contractual relationships with partners that include physician telemedicine networks, cardiology specialists, concierge clinics, and has had development contracts with major hospital systems.
In order to meet growing demand, OneFul is building a direct-to-patient ecommerce platform, and, at present, the company has secured more than 13 patents for its robotic automation, personalized medicine process methods, and pharma-tech. Our strategic roadmap entails automation of 500 unique scripts per month by Q3 of 2023, and we believe we may incrementally increase monthly capacity to 5K by Q4 and 10K by mid-2024.
*A patented gel packet system has been used in high volume production of personalized nutraceuticals and is planned to be qualified for pharmaceuticals pending bioequivalence testing.
Why Invest
Help Simplify Medications and Grow a New Kind of Pharmaceutical Solution
In OneFul’s opinion, we possess a unique opportunity built on an accredited established business combined with unmatched IP and innovation. We are on track to serve thousands of existing customers, and to reach millions of chronic disease sufferers, improving their health and daily quality of life.
As of 2021, the company had successfully raised over $7M in funding which has been instrumental in developing our IP and building a commercial operation.
Our future plans include market promotion, new partnerships, and scaling existing production operations to accommodate the growing demand for personalized therapies. Thank you for your investment in OneFul Health!
Click here to see if you qualify for our polypill!
ABOUT
HEADQUARTERS
6 Davis Drive
Durham, NC 27709
WEBSITE
View Site
OneFul is a pharmacy tech enterprise that has developed novel drug delivery products using patented automation and personalized medicine formulation software. In 2021, the company’s accredited pharma facility generated $5.8M in consolidated annual revenue, over $3M thru Q3 2022.
TEAM
Edison T Hudson
CEO/CTO/Board Member/Founder
(Fulltime Employee)
Danny M Barnes
Chief Pharmacy Officer, Board Member, President Triangle Compounding Pharmacy
(Fulltime Employee)
Deon Joubert
Chairman of Board
(Outside Board Member)
Worth Harris
Board Member
(Outside Board Member)
Eva Doss
Board Member
(Outside Board Member)
Angela Keck
Secretary/Treasurer, Chief Accountant and Human Resources Administrator
(Fulltime Employee)
Mark Friedman
Lead Financial Consultant
(Fractional Contractor )
Walter Daniels
Lead Legal Counsel
(Outside Counsel)
Staton Noel
Board of Advisors - Chief Science Advisor
(Investor, Outside Advisor)
Andrew Gunn, III
Lead Regulatory and Quality Consultant
(Fractional Contractor)
Thomas Roberg
Board of Advisors - Investor Advisor - Former Board Chairman
(Investor - Board Observer)
Gary Epler, M.D.
Board of Advisors - Lead Medical Advisor
(Fractional Consultant)
Garrett Ruhland
Board of Advisors - Digital Health Science, Web Marketing Advisor
(Fractional Consultant)
Bhaskar Venepali, PhD
Board of Advisors - Pharmaceutical Chemist, Industry Expert
(Investor, Outside Advisor)
TERMS
OneFul Health, Inc.
Overview
PRICE PER SHARE
$1
DEADLINE
Jun 2, 2023
VALUATION
$11.48M
FUNDING GOAL
$15k - $1.24M
Breakdown
MIN INVESTMENT
$250
MAX INVESTMENT
$1,235,000
MIN NUMBER OF SHARES OFFERED
15,000
MAX NUMBER OF SHARES OFFERED
1,235,000
OFFERING TYPE
Equity
ASSET TYPE
Common Stock
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Subscriber shall appoint the Board of Directors of the Company (acting as a majority) (the “Board”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the Board determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the Board for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
By subscribing to the Offering, each Stockholder agrees that inherent in the proxy rights granted to the Board of Directors are the rights to give and receive notices and communications, execute any instrument or document that the Board determines is necessary or appropriate in the exercise of its authority under this instrument, and to take all actions necessary or appropriate in the judgment of the Board for the accomplishment of the foregoing, and further, that these rights shall survive death of an individual shareholder.
Investment Incentives & Bonuses*
Time-Based:
• First Birds Bonus: Invest within the first two weeks and receive 25% bonus shares.
• Early Birds Bonus: Invest in weeks three & four and receive 15% bonus shares.
• Early Bonus: Invest in weeks five & six and receive 10% bonus shares.
Amount-Based:
• Company Bonus: Invest $1000+ and receive 5% bonus shares.
• Silver Bonus: Invest $5,000+ and receive 15% bonus shares.
• Gold Bonus: Invest $10,000+ and receive 20% bonus shares.
• Platinum Bonus: Invest $25,000+ and receive 25% bonus shares
The 10% OneFul Health Inc’s existing shareholders:
• OneFul Health Inc’s existing shareholders, customers, and partners including prescribing physicians/nurses, and contractors receive a bonus of 10% in addition to any of the above bonuses.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
OneFul Health, Inc will also offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 /share, you will receive 10 additional shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Bonus Stacking: Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and 10% OneFul Health existing shareholder bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Any expense labeled “Travel and Entertainment”. Vendor payments.
PRESS
This Daily Pill Cut Heart Attacks by Half. Why Isn’t Everyone Getting It?
Giving people an inexpensive pill containing generic drugs that prevent heart attacks — an idea first proposed 20 years ago but rarely tested — worked quite well in a new study, slashing the rate of heart attacks by more than half among those who regularly took the polypills.
ALL UPDATES
05.27.23
Why Dr. Schwab Invested in OneFul
Dr. Andrew Schwab - VC and Cardiovascular Patient Explains Why He Invested
Dr. Andrew Schwab is an investor in OneFul Health Inc based on his deep understanding of the healthcare industry and his background in technology startups. He also suffered a cardiovascular event in the past two years, and explains why OneFul's personalized polypill is so important to him personally, and why he believes it solves big problems for chronic disease patients like him.
Why he invests in OneFul Health - 3 minutes - Youtube - Why Dr. Schwab Invested in OneFul https://youtu.be/Dy3vaVhnUHw
To view the full 20-minute interview describing his journey from an investor to being a cardiovascular patient who understands first-hand the benefits of OneFul's personalized polypill, visit OneFul's website at www.oneful.health .
This testimonial may not be representative of the experience of other customers and is not a guarantee of future performance or success.
05.26.23
Why Dr. Schwab Invested in OneFul
Dr. Andrew Schwab is an investor in OneFul Health Inc based on his deep understanding of the healthcare industry and his background in technology startups. He also suffered a cardiovascular event in the past two years, and explains why OneFul's personalized polypill is so important to him personally, and why he believes it solves big problems for chronic disease patients like him.
Why he invests in OneFul Health - 3 minutes - Youtube - https://youtu.be/Dy3vaVhnUHw
To view the full 20 minute interview describing his journey from investor to being a cardiovascular patient who understands first hand the benefits of OneFul's personalized polypill, visit OneFul's website at www.oneful.health
05.18.23
Preventable Cardiovascular
Every 34 seconds in the United States, an adult dies from preventable cardiovascular disease (CVD).1 These are mothers, fathers, sisters, brothers, and friends—all gone because of a disease that is largely preventable.
- 4.1 Million not taking aspirin or blood thinners as recommended
- 67.8 Million with uncontrolled BP (≥ 130/80 mm Hg)
- 37.5 Million not taking statins as recommended
The need is great, and the market size is enormous. The North America cardiovascular drug market size is around US $ 31.85 Bn in 2022 and is projected to reach US $ 43.40 Bn in 20302.
Twenty years ago next month, a paper entitled “PolyPill - “A strategy to reduce cardiovascular disease by more than 80%” Wald, Law ( https://www.ncbi.nlm.nih.gov/pmc/articles/PMC162259/). Since then over 30,000 patients in other countries have used a version of the polypill, which has shown to reduce the risk of major cardiac events by 50% on average. So this is a way to help control this terrible disease – the polypill.
Until now, no polypill product or service exists in the USA, and no personalized, patient-specific product has been offered anywhere in the world.
Oneful is the First Pharmacy Online Platform to enable low-cost, personalized and precision cardiovascular prevention using its robotic “Single-pill combination” technology. Without this technology, accredited pharmacy infrastructure, and physician partnerships, no other company can provide such a product at an affordable price, as low as $1.00 a day. Based on our extensive industry technical knowledge and research and 20 years of operating experience in the compounding pharmacy industry, our management team believes that our patented technology and regulatory plan give us substantial competitive advantages to manufacture precision treatments that reduce cardiac events profitably at affordable costs to consumers.
Invest now, as this is going to happen. Will OneFul own the whole personalized polypill market forever? Unlikely once Big Pharma and Insurance start to see the savings of lives and budgets due to the reduction in this costly disease. Get onboard before the big guys get out their checkbooks!
1 https://millionhearts.hhs.gov/about-million-hearts/index.html
2 US Cardiovascular Drugs Market Analysis Report [2022-30] I Insights10 (https://www.insights10.com/report/us-cardiovascular-drugs-market-analysis/#:~:text=The%20North%20America%20Cardiovascular%20Drug%20Market%20size%20is,a%20CAGR%20of%205.4%25%20during%20the%20forecast%20period.)
05.05.23
OneFul and Geneticure Solution to High Blood Pressure
Making Heart Medicines Work Better with Genomics- Geneticure and OneFul Health Partner for Precision Polypills
Geneticure Inc (geneticure.com) and OneFul Health Inc (oneful.health) are teaming up to combine genomic-based formulation and personalized medicine to create precision treatments that work better for cardiovascular patients. Their joint mission is to help prevent heart attacks and strokes, focusing on better high-blood pressure treatments.
Hypertension or high blood pressure is a significant risk for several medical conditions, including coronary artery disease, stroke, heart failure, atrial fibrillation, vision loss, chronic kidney disease, and dementia. According to the CDC 2020 data, more than 670,000 deaths in the United States had hypertension as a primary or contributing cause.
Geneticure is a team of hypertension expert scientists and doctors based in Rochester, Minnesota, home of the Mayo Clinic —also an investor in Geneticure. For ten years, Geneticure's scientists have put science and innovation to work, taking personalized medicine to the next level, unmatched in the world of pharmacogenomics. With their home-collected test using the DNA on a cheek swab, Geneticure recommends which hypertension medication(s) may give the biggest drop in blood pressure. This information, supplied to specialist cardiologists, will aid OneFul Health in formulating the most effective precision polypill for each individual.
OneFul is leading the way with the first-ever precision cardiovascular polypill combining three to seven FDA-approved cardiovascular pharmaceuticals into one small capsule or gel packet. Hypertension often can only be controlled by using multiple medication classes at dosages that vary significantly among individuals. OneFul will send HIPAA-secured data generated by Geneticure to partner cardiologists or the person's doctor. Geneticure's custom report enables OneFul and its physician partners to formulate a precision polypill for hypertension optimized to each person's genetics. The optimized multi-drug prescription to control hypertension and other heart risks is transmitted to OneFul's accredited pharmaceutical facility where it is made on demand using it's patented robotic process to ensure quality. This personalized polypill is then made on demand using only certified lab-tested purity and cardiovascular drugs proven safe in trials of over 30,000 patients.
Both companies are committed to quality care and direct-to-patient services to create custom treatments that improve the quality of life and ease patient adherence. Geneticure agrees to work with OneFul Health to develop medical protocols for precision polypills and to study the benefits to patients of their joint development. The Geneticure and the OneFul Health teams are excited by the potential to improve cardiovascular treatment, bringing precision cardiology to market.
04.27.23
Will a Personalized PolyPill Reduce Your Heart Risk?
Based on our online polypill qualification survey, OneFul Health is adding 10 new candidates daily to its waiting list by for a personalized cardiovascular polypill combining 3 to 7 pills into one convenient, made-to-order capsule.
Our five-minute online HIPAA secure survey gathers the information that allows us to screen the best candidates for this personalized combination treatment. Working with HeartBeat Health's cardiologist or doctor, we can make the optimal formulation to reduce cardiovascular risks. Our combination of approved medications has been shown in clinical trials to reduce the annual risk of heart attack and stroke by up to 50%.
Will this innovation help you or your loved ones have a better chance at a healthy longer life?
Take the survey here and let’s see how we can help.
https://onefulhealth.surveysparrow.com/s/polypill-survey1/tt-3FXWQCvbrtuqmHk63HzfXm
04.23.23
Better Than AI? Closed Loop Wearable Enabled Robotic Treatments
Cardiovascular health is a medical domain where AI may be a fantastic tool for new drug and treatment discovery, but it may not be a panacea. Dr. Eric Topol reported on a continuous blood pressure monitoring bracelet about advances in non-compression-based wearable tech (https://erictopol.substack.com/p/a-continuous-blood-pressure-monitoring). A new study ( https://www.medscape.com/viewarticle/990739?src=soc_lk_share) reported about substantial variation in the blood pressure response to various antihypertensive medications between individuals, raising the possibility of need for personalized therapy. At OneFul Health, we are working with teams that will make AI will be a fantastic tool to predict the starting formulation for a precision polypill at the individual level. AIs will best integrate an individual's digital health profile, including pharmacogenomics, metabolic factors, and epigenetics. So, AIs will likely soon provide the most competent predictive personalized treatment recommendations. However, even such data-intensive AI-based treatment prescriptions cannot readily include the complete real-world individual picture, distorted by the hyper-complexity of current drug interactions, their microbiome health, diet and exercise. That is where closed-loop continuous monitoring and communication from daily wearables like an Apple Watch or Fitbit come into play. Such devices linked to AI, may bring about a whole new model for several aspects of cardiovascular preventative care. Using tech tools like Zio (https://www.irhythmtech.com/patients/how-it-works), as an in-home continuous monitor for electrophysiological factors by HeartBeat Health, (heartbeatheatlh.com), and other cardiologists is already accepted. Dynamic control in all complex systems has historically been optimized only by using near real-time feedback, as taught by famed MIT mathematician Norbert Wiener (https://en.wikipedia.org/wiki/Norbert_Wiener). With broadband infrastructure and the pervasive adoption of personal wearables, the time is here to embrace the use of closed-loop continuous monitoring and communication from daily wearables, as it has the potential to revolutionize several aspects of cardiovascular preventative care. At OneFul Health, we believe that predictive AI will unlikely be successful at preventing cardiovascular events without closing the loop at the individual level. A modernized protocol that augments AI recommendations with closed-loop continuous monitoring and communication from daily wearables to optimize precision polypills for personalized treatments can be a cardiovascular care game-changer. We believe this closed-loop approach will be better than any AI, for complex diseases such as mental health, where wearable devices or simple smartphone feedback can help formulate optimal therapies for individuals.
04.11.23
Personalized Polypill for Underserved
An important article in USA Today is "Why are so many Black patients dying from heart failure?" .Black patients are more likely to die of heart failure. Why? (https://www.usatoday.com/story/opinion/2023/04/10/black-patients-die-heart-failure-more-health-care-inequities/11552017002/ ). Dr. Munoz et al at Vanderbilt University Medical Center researched an approach to a partial solution and was published in the New England Journal of Medicine in 2019. (https://www.nejm.org/doi/full/10.1056/NEJMoa1815359) |. Until recently, the polypill concept rarely included all the right drugs or therapeutic doses to treat heart failure. Our work at www.oneful.health removes that limitation allowing individualized physician-prescribed combinations in a single personalized polypill that can include heart-failure medications while keeping out-of-pocket costs typically to $1/day. Remote access issues are addressed by cooperating with leading telemedicine specialist cardiologist networks, like partners at HeartBeat Health. This new approach to personalized cardiovascular polypills prescribed online and accurately made with robotic on-demand manufacturing can potentially reduce cardiovascular risks in populations not adequately covered by insurance in remote, underserved locations. Personalized polypills reduce most common cardiovascular risks and can be prescribed and delivered directly to at-risk individuals. The post-COVID era will show how such technologies as OneFul.Health has developed can be employed to address health equity.
03.29.23
HeartBeat Health and Oneful Health For Personalized Cardiology
Personalized Medicine Meets Virtual Care Cardiology:
Heartbeat Health and OneFul Health Partner to Prevent Heart Attacks and Strokes
March 28, 2023, New York, NY and Research Triangle Park, NC
Heartbeat Health and OneFul Health have teamed up to bring telemedicine and personalized medicine together, providing individuals with unique treatments to help prevent heart attacks and strokes, delivered right to their homes.
Heartbeat Health is founded by Dr. Jeffrey Wessler, a cardiologist-entrepreneur who leveraged his academic expertise to create a new standard for Virtual-First Cardiology care. Heartbeat is revolutionizing cardiovascular care, one virtual intervention at a time, and is the perfect partner for OneFul. This combination of innovative healthcare technology companies will deliver direct-to-patient personalized cardiovascular disease prevention and management services.
OneFul is leading the way with the first-ever precision cardiovascular polypill combining three to seven FDA-approved cardiovascular pharmaceuticals into one small capsule. Using only certified lab-tested purity and proven safe cardiovascular drugs trialed in over 30,000 patients, OneFul formulates personalized pharmaceutical treatments with its patented pharm tech automation platform, invented by founder and robotics expert Edison Hudson.
OneFul will send HIPAA-controlled data about pre-qualified polypill patients to Heartbeat, whose cardiologists will qualify patients for personalized polypill treatments, creating custom prescriptions that match each patient's medical needs. Their multi-drug prescription is then transmitted to OneFul's accredited pharmaceutical facility, managed by 20+ year veteran Pharmacist Danny Barnes. His PharmD team reviews and accurately fills each script using high-accuracy technology.
Both companies are committed to quality care and direct-to-patient services, making specialized cardiology consultations accessible and fast to schedule, along with custom treatments that make life and medication adherence easier for patients. Plans include integrating pharmacogenomics and in-home biomarker testing to improve treatment effectiveness further and reduce adverse effects. HeartBeat agrees to work with OneFul Health to create medical protocols for precision polypills that can be applied to any patient by their national network of cardiologists.
Heartbeat Health and OneFul Health teams are excited by the potential to improve cardiovascular treatment, providing the best in telemedicine and personalized medicine to prevent heart attacks and strokes and ushering in a new era of personalized cardiovascular care.
onefulhealth.com/ 
heartbeathealth.com
03.21.23
What is the Market for Personalized Polypill
Watch Edison Hudson, CEO/Founder speak about Oneful Personalized, Precision, Preventative Polypill - https://youtu.be/FEbxfbvTrRM
Imagine having the power to change lives and prevent heart disease in millions of Americans. With our Cardiovascular Precision Preventative Polypill, or CVD-P3, we have the opportunity to make a significant impact in the world of medicine. Some of you may have had questions about our product and its potential impact. Rest assured, the market for our product is enormous. Over 14 million Americans have diagnosed coronary artery disease, and a large portion of these individuals could benefit from using CVD-P3.
Our product is specially designed for patients who take multiple post-operation drugs to reduce risk. This includes patients who have received stents and coronary artery bypass graft surgery, which amounts to 2 million and 340,000 people per year, respectively. And it doesn't stop there. CVD-P3 can also be formulated to address specific genomic risk factors, common in some families - 27.8 million people over 20 years of age.
With the impact of COVID-19, the risks for heart disease have only increased. Dr. Eric Topol, in his recent article on Substack, mentions the 1.7-fold risk of heart attack and 1.6-fold increased risk of stroke. This means that there is an even greater need for preventative measures like CVD-P3.
But let's talk about the numbers. Our model predicts that we can achieve revenue of $100M by serving just 1.5 million customers per year - a feasible number with 25 of our robotic compounders. And that's just the beginning. Imagine the potential impact of our future pipeline, which includes addressing diabetes, metabolic diseases, and mental health.
So, let's take control of the future of medicine and make a real difference in the lives of millions. Join us in our mission to prevent heart disease and pave the way for a healthier world. Listen to Edison Hudson, our CEO explain more about our revolutionary CVD-P3 personalized product.
Data Sources: https://www.nih.gov/news-events/nih-research-matters/bypass-surgery-shows-advantage ; https://idataresearch.com/stents-implanted-per-year-in-the-u-s/#:~:text=iData%20Research%2C%20a%20leading%20international%20market%20research%20and,stents%20implanted%20per%20year%20in%20the%20United%20States. ; https://idataresearch.com/new-study-shows-approximately-340000-cabg-procedures-per-year-in-the-united-states/#:~:text=According%20to%20a%20new%20cardiac%20surgery%20study%20by,grafted%20onto%20the%20heart%20to%20bypass%20blocked%20arteries. ; https://www.ahajournals.org/doi/10.1161/JAHA.119.012364#:~:text=Using%20a%20representative%20sample%20of%20the%20US%20population%2C,cardiovascular%20disease%20can%20be%20identified%20using%20family%20history. ; https://erictopol.substack.com/p/heart-attacks-and-strokes-late-after
StartEngine Forward Looking Statements:
The statements in the article are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this update are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
03.16.23
Unaffected by SVB issues
OneFul Health Inc and wholly owned subsidiary, Triangle Compounding Pharmacy, are not directly impacted by the current Silicon Valley Bank, Signature Bank situation. Our accounts are all with Truist Bank at this time.
Stack Owner's Bonus & Rewards!
Members get an extra 10% shares in addition to rewards below!
REWARDS
$250
Earn 10% Bonus Shares
Earn 10% bonus shares in this investment and all eligible investments for an entire year. If you are not already an Owners bonus holder, you can join now, for $275, billed annually.
$1,000
Company Bonus
Invest $1000+ and receive 5% bonus shares.
$5,000
Silver Bonus
Invest $5,000+ and receive 15% bonus shares.
$10,000
Gold Bonus
Invest $10,000+ and receive 20% bonus
$25,000
Platinum Bonus
Invest $25,000+ and receive 25% bonus shares
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Adam Sampson
8 INVESTMENTS
3 months ago
1
0